Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na

This publication has 22 references indexed in Scilit:

• The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130–230 RSV-A protein
  Vaccine, 1999
• Relationship of Serum Antibody to Risk of Respiratory Syncytial Virus Infection in Elderly Adults
  The Journal of Infectious Diseases, 1998
• Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide.
  The Journal of Infectious Diseases, 1997
• Nosocomial Respiratory Syncytial Virus Infections: Prevention and Control in Bone Marrow Transplant Patients
  Infection Control & Hospital Epidemiology, 1997
• Induction of Protective Immunity in Rodents by Vaccination with a Prokaryotically Expressed Recombinant Fusion Protein Containing a Respiratory Syncytial Virus G Protein Fragment
  Virology, 1997
• Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis
  The Pediatric Infectious Disease Journal, 1996
• Hydrophobicity Engineering to Increase Solubility and Stability of a Recombinant Protein from Respiratory Syncytial Virus
  European Journal of Biochemistry, 1995
• Progress toward the development of a respiratory syncytial virus vaccine
  Pediatric Pulmonology, 1995
• An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines
  Virus Research, 1994
• Humoral immunity to respiratory syncytial virus infection in the elderly
  Journal of Medical Virology, 1992